Toll Free: 1-888-928-9744

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2016

Published: Apr 20, 2016 | Pages: 192 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2016', provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Chronic Renal Failure)
- The report reviews pipeline therapeutics for Chronic Kidney Disease (Chronic Renal Failure) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Chronic Kidney Disease (Chronic Renal Failure) therapeutics and enlists all their major and minor projects
- The report assesses Chronic Kidney Disease (Chronic Renal Failure) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Chronic Kidney Disease (Chronic Renal Failure

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Content 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Chronic Kidney Disease (Chronic Renal Failure) Overview 8 Therapeutics Development 9 Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure) - Overview 9 Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure) - Comparative Analysis 10 Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics under Development by Companies 11 Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics under Investigation by Universities/Institutes 13 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Unknown Stage Products 17 Chronic Kidney Disease (Chronic Renal Failure) - Products under Development by Companies 18 Chronic Kidney Disease (Chronic Renal Failure) - Products under Investigation by Universities/Institutes 21 Chronic Kidney Disease (Chronic Renal Failure) - Companies Involved in Therapeutics Development 22 Acceleron Pharma, Inc. 22 Angion Biomedica Corp. 23 Astellas Pharma Inc. 24 Bayer AG 25 Bio-inRen 26 BioAegis Therapeutics, Inc. 27 Boryung Pharmaceutical Co., Ltd. 28 Complexa, Inc. 29 Evotec AG 30 F. Hoffmann-La Roche Ltd. 31 Gilead Sciences, Inc. 32 Intercept Pharmaceuticals, Inc. 33 Ionis Pharmaceuticals, Inc. 34 Lupin Limited 35 Nippon Zoki Pharmaceutical Co., Ltd. 36 OPKO Health, Inc. 37 Otsuka Holdings Co., Ltd. 38 Prismic Pharmaceuticals, Inc. 39 Prolong Pharmaceuticals, LLC 40 ProMetic Life Sciences Inc. 41 Reata Pharmaceuticals, Inc. 42 Red Glead Discovery AB 43 RegenMedTX, LLC 44 Resverlogix Corp. 45 Sphaera Pharma Pvt. Ltd. 46 Stelic Institute & Co., Inc. 47 Thrasos Therapeutics Inc. 48 Toray Industries, Inc. 49 VBS Pharmaceuticals 50 Vicore Pharma AB 51 Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Assessment 52 Assessment by Monotherapy Products 52 Assessment by Combination Products 53 Assessment by Target 54 Assessment by Mechanism of Action 57 Assessment by Route of Administration 60 Assessment by Molecule Type 62 Drug Profiles 64 (palmidrol + silibinin) - Drug Profile 64 ambrisentan - Drug Profile 65 ANG-3070 - Drug Profile 67 ANG-3281 - Drug Profile 68 ANG-3586 - Drug Profile 69 ANG-4011 - Drug Profile 70 apabetalone - Drug Profile 71 AS-2444697 - Drug Profile 74 ASP-6858 - Drug Profile 75 bardoxolone methyl - Drug Profile 76 BR-05001 - Drug Profile 79 BRN-1889 - Drug Profile 80 C-21 - Drug Profile 81 calcium succinate - Drug Profile 83 CAR Peptide - Drug Profile 84 cardiotoxin - Drug Profile 85 Cell Therapy for Chronic Kidney Disease and Type-2 diabetes - Drug Profile 86 CXA-10 - Drug Profile 87 Drug for Kidney Diseases - Drug Profile 88 Drugs to Inhibit CYP24 for Secondary Hyperparathyroidism, Chronic Kidney Disease and Oncology - Drug Profile 89 finerenone - Drug Profile 90 INT-767 - Drug Profile 91 IONIS-FXIRx - Drug Profile 93 KBP-5074 - Drug Profile 94 NZ-419 - Drug Profile 95 obinutuzumab - Drug Profile 96 PBI-4050 - Drug Profile 100 PBI-4419 - Drug Profile 102 Protein to Activate BMP-7 for Kidney Diseases, Metabolic Disorders and Osteoarthritis - Drug Profile 103 Recombinant Plasma Gelsolin Replacement for Renal Disease - Drug Profile 105 rivaroxaban - Drug Profile 106 Sanguinate - Drug Profile 112 Small Molecule to Agonize CaSR for Chronic Kidney Disease and Primary Hyperparathyroidism - Drug Profile 114 Small Molecule to Inhibit Sodium-Phosphate Cotransporter 2b for CKD and Hypertension - Drug Profile 115 Small Molecules for Chronic Kidney Disease - Drug Profile 116 Small Molecules for Chronic Kidney Disease - Drug Profile 117 Small Molecules to Inhibit Soluble Epoxide Hydrolase for Chronic Kidney Disease - Drug Profile 118 Small Molecules to Inhibit SphK2 for Oncology, Kideny Disease, Autoimmune Disorders, Fibrosis and Neurodegenerative Diseases - Drug Profile 119 sotatercept - Drug Profile 120 SP-20103 - Drug Profile 122 SPR-494 - Drug Profile 123 STNM-310 - Drug Profile 124 Synthetic Peptide to Modulate GHSR for Chronic Kidney Disease - Drug Profile 125 Synthetic Peptides for Chronic Kidney Disease - Drug Profile 126 TNT-009 - Drug Profile 127 tolvaptan - Drug Profile 128 torsemide ER - Drug Profile 131 TRC-101 - Drug Profile 132 Vida-5 - Drug Profile 133 Chronic Kidney Disease (Chronic Renal Failure) - Recent Pipeline Updates 134 Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects 176 Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products 178 Chronic Kidney Disease (Chronic Renal Failure) - Product Development Milestones 180 Featured News & Press Releases 180 Appendix 187 Methodology 187 Coverage 187 Secondary Research 187 Primary Research 187 Expert Panel Validation 187 Contact Us 187 Disclaimer 188
List of Tables
Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H1 2016 13 Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure) - Comparative Analysis, H1 2016 14 Number of Products under Development by Companies, H1 2016 15 Number of Products under Development by Companies, H1 2016 (Contd..1) 16 Number of Products under Investigation by Universities/Institutes, H1 2016 17 Comparative Analysis by Late Stage Development, H1 2016 18 Comparative Analysis by Clinical Stage Development, H1 2016 19 Comparative Analysis by Early Stage Development, H1 2016 20 Comparative Analysis by Unknown Stage Development, H1 2016 21 Products under Development by Companies, H1 2016 22 Products under Development by Companies, H1 2016 (Contd..1) 23 Products under Development by Companies, H1 2016 (Contd..2) 24 Products under Investigation by Universities/Institutes, H1 2016 25 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Acceleron Pharma, Inc., H1 2016 26 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Angion Biomedica Corp., H1 2016 27 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Astellas Pharma Inc., H1 2016 28 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Bayer AG, H1 2016 29 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Bio-inRen, H1 2016 30 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by BioAegis Therapeutics, Inc., H1 2016 31 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boryung Pharmaceutical Co., Ltd., H1 2016 32 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Complexa, Inc., H1 2016 33 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Evotec AG, H1 2016 34 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 35 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Gilead Sciences, Inc., H1 2016 36 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Intercept Pharmaceuticals, Inc., H1 2016 37 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Ionis Pharmaceuticals, Inc., H1 2016 38 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Lupin Limited, H1 2016 39 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Nippon Zoki Pharmaceutical Co., Ltd., H1 2016 40 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by OPKO Health, Inc., H1 2016 41 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 42 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Prismic Pharmaceuticals, Inc., H1 2016 43 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Prolong Pharmaceuticals, LLC, H1 2016 44 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by ProMetic Life Sciences Inc., H1 2016 45 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Reata Pharmaceuticals, Inc., H1 2016 46 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Red Glead Discovery AB, H1 2016 47 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by RegenMedTX, LLC, H1 2016 48 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Resverlogix Corp., H1 2016 49 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Sphaera Pharma Pvt. Ltd., H1 2016 50 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Stelic Institute & Co., Inc., H1 2016 51 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Thrasos Therapeutics Inc., H1 2016 52 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Toray Industries, Inc., H1 2016 53 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by VBS Pharmaceuticals, H1 2016 54 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vicore Pharma AB, H1 2016 55 Assessment by Monotherapy Products, H1 2016 56 Assessment by Combination Products, H1 2016 57 Number of Products by Stage and Target, H1 2016 59 Number of Products by Stage and Mechanism of Action, H1 2016 62 Number of Products by Stage and Route of Administration, H1 2016 65 Number of Products by Stage and Molecule Type, H1 2016 67 Chronic Kidney Disease (Chronic Renal Failure) Therapeutics - Recent Pipeline Updates, H1 2016 138 Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, H1 2016 180 Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects (Contd..1), H1 2016 181 Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products, H1 2016 182 Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products (Contd..1), H1 2016 183


List of Figures
Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H1 2016 13 Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure) - Comparative Analysis, H1 2016 14 Number of Products under Development by Companies, H1 2016 15 Comparative Analysis by Clinical Stage Development, H1 2016 19 Comparative Analysis by Early Stage Products, H1 2016 20 Assessment by Monotherapy Products, H1 2016 56 Number of Products by Top 10 Targets, H1 2016 58 Number of Products by Stage and Top 10 Targets, H1 2016 58 Number of Products by Top 10 Mechanism of Actions, H1 2016 61 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 61 Number of Products by Routes of Administration, H1 2016 64 Number of Products by Stage and Routes of Administration, H1 2016 64 Number of Products by Molecule Types, H1 2016 66 Number of Products by Stage and Molecule Types, H1 2016 66

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global fluorotelomers market size is anticipated to be valued at USD 539.3 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing application scope in fire fighting systems owing to growing safety concerns is likely to dri

Read More...

Global alpha olefins market size is likely to be valued at USD 10.7 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing polyethylene demand for use in plastic production is anticipated to drive market growth. Growing ap

Read More...

Global aerospace plastics market size is likely to be valued at USD 13.48 billion by 2020; as per a new research report by Radiant Insights, Inc. Growing application scope of lightweight materials in aerospace industry is likely to drive market growt

Read More...

Global data center UPS market size is estimated to reach USD 5.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Declining tolerance levels pertaining to data loss along with amplifying acceptance of cloud computing is likely

Read More...

Global automotive collision repair market is expected to be valued at USD 196.97 billion by 2020, as per a new research report by Radiant Insights, Inc. The industry is expected to witness significant growth owing to increasing number of on-road vehi

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify